Immunoconjugate Therapy of Hematologic Malignancies PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Immunoconjugate Therapy of Hematologic Malignancies PDF full book. Access full book title Immunoconjugate Therapy of Hematologic Malignancies by Steven T. Rosen. Download full books in PDF and EPUB format.
Author: Steven T. Rosen Publisher: Springer Science & Business Media ISBN: 1461530768 Category : Medical Languages : en Pages : 293
Book Description
The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel that the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of CANCER TREATMENT AND RESEARCH explores the current state of the art of immunoconjugate therapy of hematologic malignancies. Immunoconjugate Therapy of Hematologic Malignancies provides an update of a rapidly advancing field. The preliminary experience of a number of investigators suggests a role for targeted therapy in the treatment of hematologic malignancies. At the present time, immunoconjugates have, in most instances, been reserved for patients with advanced refractory disease. However, it is anticipated in the future that these reagents will be utilized as a complement to traditional therapy or as post-remission consolidation in patients with minimal residual disease. The obstacles have been defined; solutions will require further research and creative imagination.
Author: Steven T. Rosen Publisher: Springer Science & Business Media ISBN: 1461530768 Category : Medical Languages : en Pages : 293
Book Description
The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel that the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of CANCER TREATMENT AND RESEARCH explores the current state of the art of immunoconjugate therapy of hematologic malignancies. Immunoconjugate Therapy of Hematologic Malignancies provides an update of a rapidly advancing field. The preliminary experience of a number of investigators suggests a role for targeted therapy in the treatment of hematologic malignancies. At the present time, immunoconjugates have, in most instances, been reserved for patients with advanced refractory disease. However, it is anticipated in the future that these reagents will be utilized as a complement to traditional therapy or as post-remission consolidation in patients with minimal residual disease. The obstacles have been defined; solutions will require further research and creative imagination.
Author: Beverly A. Teicher Publisher: Springer Science & Business Media ISBN: Category : Medical Languages : en Pages : 338
Book Description
This comprehensive review of existing and potential anticancer drugs and therapies by leading researchers from academia, government laboratories, and pharmaceutical companies offers essential insight into what has been accomplished and where the experimental therapy of cancer is going. The authoritative contributors illuminate the current status of the major molecules of cancer treatment, ranging from the nitrogen mustards through platinum complexes to interferons, cytokines, growth factors and their inhibitors, and on to immunotoxins, antisense oligonucleotides, and gene therapy. A companion volume by the same editor (Anticancer Drug Development Guide: Preclinical and Clinical Screening and Approval) details the processes by which new anticancer drugs are approved. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
Author: Brian A. Baldo Publisher: Springer ISBN: 3319304720 Category : Medical Languages : en Pages : 623
Book Description
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.
Author: Iwao Ojima Publisher: ISBN: Category : Medical Languages : en Pages : 388
Book Description
Anticancer Agents: Frontiers in Cancer Chemotherapy describes cutting-edge approaches in the development of anticancer agents for chemotherapy.
Author: Stefan Dübel Publisher: John Wiley & Sons ISBN: 3527329374 Category : Science Languages : en Pages : 2538
Book Description
Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle.
Author: C. Dean Buckner Publisher: Springer Science & Business Media ISBN: 1461520134 Category : Medical Languages : en Pages : 414
Book Description
Technical and Biological Components of Marrow Transplantation presents up to date information on the scientific and technological advances that will extend and improve the clinical application of bone marrow transplantation. The book includes the latest information on chronic myeloid leukemia and thalassemia; advances in supportive care: cytokines and progenitor expansion; and cord stem cell technology. Soon more of patients will receive marrow transplants as part of the therapy for solid tumors and metabolic disease than for the treatment of hematologic disease. The contributors to this volume describe some of these applications, hinting at yet further, exciting possibilities.
Author: Carmen Avendaño Publisher: Elsevier ISBN: 0444626670 Category : Science Languages : en Pages : 767
Book Description
Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design. - Presents information in a clear and concise way using a large number of figures - Historical background provides insights on how the process of drug discovery in the anticancer field has evolved - Extensive references to primary literature
Author: Marc Damelin Publisher: Springer ISBN: 3319781545 Category : Medical Languages : en Pages : 358
Book Description
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Author: Bharat B. Mittal Publisher: Springer Science & Business Media ISBN: 1461557690 Category : Medical Languages : en Pages : 308
Book Description
Recent advances in radiation oncology have depended upon and are intertwined with subsequent scientific discoveries and the development of new techniques in the fields of radiation and molecular biology, physics, electrical engineering, surgery, and medical oncology. This volume describes how some of the recent discoveries in the radiological sciences have influenced the way radiation oncology is practised. As there are many advances in this field, the Editors have chosen to concentrate on selected topics in clinical radiotherapy, radiation physics and biology, and technical innovations that have had a major impact on radiation oncology in the past twenty years. It is hoped that the techniques described in this volume will increase tumor control and prolong patient survival and at the same time decrease radiation-induced side effects and complications.
Author: Steven T. Rosen
Author: Steven T. Rosen
Author: Beverly A. Teicher
Author: Brian A. Baldo
Author: Iwao Ojima
Author: Stefan Dübel
Author: Bruce D. Cheson
Author: C. Dean Buckner
Author: Carmen Avendaño
Author: Marc Damelin
Author: Bharat B. Mittal